-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $22

Benzinga·11/05/2026 22:30:14
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $32 to $22.